1. Search Result
Search Result
Results for "

NAD(P)H oxidation

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Peptides

3

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2993

    ICDH; IDH

    Isocitrate Dehydrogenase (IDH) Metabolic Disease Cancer
    Isocitrate dehydrogenase, Porcine heart (ICDH) is a citric acid or tricarboxylic acid cycle enzyme, is often used in biochemical studies. Isocitrate dehydrogenase catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate and reduces NAD(P) + to NAD(P)H, it plays important roles in cellular metabolism .
    Isocitrate dehydrogenase, Porcine heart
  • HY-P2947

    Aldehyde dehydrogenase (NAD(P))

    Aldehyde Dehydrogenase (ALDH) Others Cancer
    ALDH (Aldehyde dehydrogenase (NAD(P))) catalyzes the oxidation of aldehydes into their corresponding carboxylic acids with the concomitant reduction of the cofactor NAD(P) into NAD(P)H, is often used in biochemical studies. The ALDHs are one of many enzyme systems the body utilizes to alleviate aldehyde stress .
    ALDH
  • HY-113324
    NADPH
    Maximum Cited Publications
    10 Publications Verification

    Endogenous Metabolite Cancer
    NADPH is a coenzyme of glutathione reductase (GR), thioredoxin reductase (TrxR) and NADPH oxidase (NOX), and participates in redox reactions as a hydrogen donor. NADPH has the characteristic of selectively participating in the regulation of cellular redox homeostasis. NADPH exerts antioxidant activity and resists reactive oxygen species (ROS) damage by providing reducing equivalents for the regeneration of glutathione (GSH) and thioredoxin (Trx); at the same time, it acts as a substrate of NOX to generate superoxide anions, mediating oxidative stress and immune response. NADPH participates in maintaining the intracellular reducing environment, biosynthesis and regulating gene expression (such as the Nrf2 pathway), and is mainly used in the study of oxidative stress-related diseases (such as cardiovascular diseases, neurodegenerative diseases, cancer) and immune regulation mechanisms .
    NADPH
  • HY-128895
    KL1333
    1 Publications Verification

    Quinone Reductase Mitochondrial Metabolism Metabolic Disease
    KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures .
    KL1333
  • HY-P3186

    Endogenous Metabolite Metabolic Disease
    Glucose dehydrogenase, recombinant Microorganisms is a FDA-dependent oxidoreductase. Glucose dehydrogenase (GDH) catalyzes the oxidation of β-D-glucose to β-D-glucono-1,5-lactone with simultaneous reduction of the cofactor NADP + to NADPH or, to a lesser extent, NAD + to NADH. Glucose dehydrogenase (GDH) accepts both NAD + and NADP + as cofactors and can be used for the regeneration of NADH and NADPH .
    Glucose dehydrogenase, recombinant Microorganisms
  • HY-W015422

    PARP Metabolic Disease
    1,5-Isoquinolinediol is a potent PARP inhibitor, with an IC50 of 0.18-0.37 μM. 1,5-Isoquinolinediol attenuates diabetes-induced NADPH oxidase-derived oxidative stress in retina .
    1,5-Isoquinolinediol
  • HY-172227

    Mitochondrial Metabolism Cardiovascular Disease
    S-15176 is an inhibitor of the mitochondrial permeability transition pore (PTP). S-15176 inhibits mitochondrial swelling induced by tert-butylhydroperoxide with an IC50 value of 45.7 μM. S-15176 inhibits PTP opening, prevents mitochondrial membrane potential dissipation and NAD(P)H oxidation, and increases mitochondrial calcium loading capacity. S-15176 is promising for research of ischemia-reperfusion injury .
    S-15176
  • HY-P2993A

    ICDH, Microorganism; IDH, Microorganism

    Isocitrate Dehydrogenase (IDH) Metabolic Disease
    Isocitrate dehydrogenase, Microorganism (IDH) (EC 1.1.1.42) is a citric acid or tricarboxylic acid cycle enzyme, is often used in biochemical studies. Isocitrate dehydrogenase catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate and reduces NAD(P) + to NAD(P)H, it plays important roles in cellular metabolism .
    Isocitrate dehydrogenase, Microorganism
  • HY-P2800A

    Endogenous Metabolite Metabolic Disease
    Diaphorase from Clostridium sp. is responsible for catalyzing the oxidation of NADH or NADPH and is involved in regulating cellular energy metabolism .
    Diaphorase, clostridium sp.
  • HY-125863B

    G6PD (yeast, recombinant)

    Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    Glucose 6-phosphate dehydrogenase (yeast, recombinant) is the rate-limiting enzyme of the pentose phosphate pathway and a major source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, and cytochrome P450 systems. Glucose 6-phosphate dehydrogenase helps cells resist oxidative stress and regulates metabolic rates. It holds potential for research in fields such as diabetes, endothelial dysfunction, cancer, and cardiomyopathy .
    Glucose 6-phosphate dehydrogenase (yeast, recombinant)
  • HY-125863

    G6PD

    Endogenous Metabolite Metabolic Disease Cancer
    Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy .
    Glucose-6-phosphate dehydrogenase, Microorganism
  • HY-167879A

    Fungal Fatty Acid Synthase (FASN) Infection Inflammation/Immunology
    NPD6433 is a triazenyl indole with broad-spectrum activity against all screening fungal strains. NPD6433 targets the enoyl reductase domain of fatty acid synthase 1 (Fas1), covalently inhibiting its flavin mononucleotide-dependent NADPH-oxidation activity and arresting essential fatty acid biosynthesis .
    NPD6433
  • HY-100986
    L-NIO dihydrochloride
    1 Publications Verification

    NO Synthase Cardiovascular Disease
    L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with Kis of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively . L-NIO dihydrochloride induces a consistentfocal ischemic infarctin rats .
    L-NIO dihydrochloride
  • HY-100986B

    NO Synthase Cardiovascular Disease
    L-NIO is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with Kis of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively . L-NIO induces a consistentfocal ischemic infarctin rats .
    L-NIO
  • HY-N6237

    Aminotransferases (Transaminases) Apoptosis Cancer
    Aspulvinone O is a selective inhibitor of glutamate oxaloacetate aminotransferase GOT1. Aspulvinone O inhibits glutamine metabolism and reduces NADPH production, thereby inducing oxidative stress and apoptosis in pancreatic ductal adenocarcinoma (PDAC) cells. Aspulvinone O inhibits PDAC cell proliferation in vitro and tumor growth in xenograft models .
    Aspulvinone O
  • HY-167879

    Fungal Fatty Acid Synthase (FASN) Infection Inflammation/Immunology
    (Rac)-NPD6433 is a racemate of NPD6433. NPD6433 is a triazenyl indole with broad-spectrum activity against all screening fungal strains. NPD6433 targets the enoyl reductase domain of fatty acid synthase 1 (Fas1), covalently inhibiting its flavin mononucleotide-dependent NADPH-oxidation activity and arresting essential fatty acid biosynthesis .
    (Rac)-NPD6433
  • HY-125862

    EC 1.6.4.2; GR

    Calcineurin Reactive Oxygen Species Cardiovascular Disease Neurological Disease
    Glutathione reductase, baker's yeast (EC 1.6.4.2) is a reductase. Glutathione reductase, baker's yeast eliminates intracellular ROS. Glutathione reductase, baker's yeast reduces oxidized glutathione (GSSG) to reduced glutathione (GSH) using NADPH as an electron donor. Glutathione reductase, baker's yeast exerts antioxidant activity. Glutathione reductase is mainly used to study diseases associated with oxidative stress, such as Parkinson's disease and sickle cell anemia .
    Glutathione Reductase, baker's yeast
  • HY-123962
    G6PD activator AG1
    5 Publications Verification

    NADPH Oxidase Metabolic Disease
    G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) agonist with an EC50 of 3 μM. G6PD is an oxidoreductase that catalyzes the oxidation of glucose-6-phosphate to 6-phosphogluconolactone and the simultaneous reduction of NAD phosphate (NADP) to reduced NADP (NADPH). G6PD activator AG1 can reduce hemolysis of human erythrocytes .
    G6PD activator AG1
  • HY-113777

    22-Hydroxy Docosahexaenoic acid; 22-OH DHA

    Cytochrome P450 Metabolic Disease
    22-HDHA (22-Hydroxy Docosahexaenoic acid) is an oxidation product of docosahexaenoic acid. In vitro, it is formed upon incubation of rat liver microsomes with DHA and NADPH and also by the human cytochrome P450 (CYP) isoform CYP4F3B in BTI-TN-5B1-4 microsomes. Serum levels of 22-HDHA increase following dietary DHA supplementation in humans.
    22-HDHA
  • HY-12119B

    NO Synthase Neurological Disease Inflammation/Immunology
    GW274150 (dihydrochloride) is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 (dihydrochloride) displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 (dihydrochloride) exerts a protective role in an acute model of lung injury inflammation .
    GW274150 dihydrochloride
  • HY-12119
    GW274150
    2 Publications Verification

    NO Synthase Neurological Disease Inflammation/Immunology
    GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 also displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 exerts a protective role in an acute model of lung injury inflammation .
    GW274150
  • HY-12119A
    GW274150 phosphate
    2 Publications Verification

    NO Synthase Neurological Disease Inflammation/Immunology
    GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 phosphate displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 phosphate exerts a protective role in an acute model of lung injury inflammation .
    GW274150 phosphate
  • HY-P0109

    Cathepsin Others
    (S,S)-Z-FA-FMK is a cell-permeable, irreversible cathepsin B inhibitor. (S,S)-Z-FA-FMK blocks LPS-induced production of IL-1α and IL-1β. (S,S)-Z-FA-FMK can be used as a negative control for caspase-1 and caspase-2 inhibitors because it lacks an aspartic acid residue at the P1 position .
    (S,S)-Z-FA-FMK

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: